Related references
Note: Only part of the references are listed.Indomethacin induces cellular morphological change and migration via epithelial-mesenchymal transition in A549 human lung cancer cells: A novel cyclooxygenase-inhibition-independent effect
Tomoko Kato et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Celecoxib Promotes c-FLIP Degradation through Akt-Independent Inhibition of GSK3
Shuzhen Chen et al.
CANCER RESEARCH (2011)
The Number of Lymph Node Metastases as a Prognostic Factor in Patients With N1 Non-small Cell Lung Cancer
Sirisha Jonnalagadda et al.
CHEST (2011)
Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways
Olorunseun O. Ogunwobi et al.
CLINICAL & EXPERIMENTAL METASTASIS (2011)
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group
Andrea Koch et al.
EUROPEAN JOURNAL OF CANCER (2011)
The Role of Polymeric Immunoglobulin Receptor in Inflammation-Induced Tumor Metastasis of Human Hepatocellular Carcinoma
Jing Ai et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Celecoxib Antagonizes the Cytotoxicity of Cisplatin in Human Esophageal Squamous Cell Carcinoma Cells by Reducing Intracellular Cisplatin Accumulation
Le Yu et al.
MOLECULAR PHARMACOLOGY (2011)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines
Seok-Woo Park et al.
ANTI-CANCER DRUGS (2010)
Activated PI3K/Akt/COX-2 Pathway Induces Resistance to Radiation in Human Cervical Cancer HeLa Cells
Shu Xia et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2010)
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kai Kessenbrock et al.
CELL (2010)
Lung cancer progression and metastasis from the prognostic point of view
Kentaro Inamura et al.
CLINICAL & EXPERIMENTAL METASTASIS (2010)
KRAS Mutant Lung Cancer Cells Are Differentially Responsive to MEK Inhibitor Due to AKT or STAT3 Activation: Implication for Combinatorial Approach
Young-Kwang Yoon et al.
MOLECULAR CARCINOGENESIS (2010)
Management and Prognosis in Synchronous Solitary Resected Brain Metastasis from Non-Small-Cell Lung Cancer
Alexander V. Louie et al.
CLINICAL LUNG CANCER (2009)
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells
Young-Kwang Yoon et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Transforming growth factor-β1 increases cell migration and β1 integrin up-regulation in human lung cancer cells
Yi-Chin Fong et al.
LUNG CANCER (2009)
Cyclooxygenase-2 Expression Is Related to the Epithelial-to-Mesenchymal Transition in Human Colon Cancers
Tae Jung Jang et al.
YONSEI MEDICAL JOURNAL (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Cyclooxygenase-2 expression during immortalization and breast cancer progression
Xiangshan Zhao et al.
CANCER RESEARCH (2008)
Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-β through a PGE2-dependent mechanisms
Jason R. Neil et al.
CARCINOGENESIS (2008)
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib
Mary J. Fidler et al.
CLINICAL CANCER RESEARCH (2008)
Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib plus chemotherapy - Cancer and leukemia group B trial 30203
Martin J. Edelman et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gefitinib plus celecoxilb in chernotherapy-naive patients with stage IIIB/IV non-small cell lung cancer - A phase II study from the Hoosier Oncology Group
Anuj Agarwala et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Etodolac, a selective cyclooxygenase-2 inhibitor, induces Upregulation of e-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo
Asako Okamoto et al.
UROLOGY (2008)
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation
Alessandra Fabi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Stage IA non-small cell lung cancer: Vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy
Tomoshi Tsuchiya et al.
LUNG CANCER (2007)
Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma
BI Rini et al.
CANCER (2006)
TGF-β1 induces human alveolar epithelial to mesenchymal cell transition (EMT) -: art. no. 56
H Kasai et al.
RESPIRATORY RESEARCH (2005)
Effects of etodolac, a selective cyclooxygenase-2 inhibitor, on the expression of E-cadherin-catenin complexes in gastrointestinal cell lines
M Noda et al.
JOURNAL OF GASTROENTEROLOGY (2002)
Regulation of Raf-Akt cross-talk
K Moelling et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
ERK negatively regulates the epidermal growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase
CF Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-κB
E Niederberger et al.
FASEB JOURNAL (2001)